TrialHepatology (Baltimore, Md.)2019

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis.

Michael Trauner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.